Using Trial Eligibility to Personalize Statin Therapy Appears No More Accurate Than a Coin Flip in Determining High-Risk Status

JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):231-233. doi: 10.1016/j.jcmg.2017.02.019. Epub 2017 Jun 14.

Authors

Roger S Blumenthal¹, M Imran Aslam², J William McEvoy²

Affiliations

¹ Ciccarone Center for the Prevention of Heart Disease, The Johns Hopkins Medical Center, Baltimore, Maryland. Electronic address: rblument@jhmi.edu.
² Ciccarone Center for the Prevention of Heart Disease, The Johns Hopkins Medical Center, Baltimore, Maryland.

PMID: 28624410
DOI: 10.1016/j.jcmg.2017.02.019

No abstract available

Keywords: cardiovascular disease; guideline; lipoproteins; primary prevention.

Publication types

Editorial
Comment

MeSH terms

Coronary Artery Disease*
Eligibility Determination
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Primary Prevention

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors